Skip to main content
main-content
Top

07-10-2019 | Renal cell carcinoma | Video | Article

Researcher comment: A novel CXCR4 inhibitor for RCC and a novel immunotherapy endpoint

David McDermott talks through his renal cell carcinoma research exploring the use of a novel oral CXCR4 inhibitor and treatment-free survival as an alternative endpoint for immunotherapy trials (4:03).

Read the transcript here


This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Image Credits